{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Adenocarcinoma", "query": { "condition": "Colorectal Adenocarcinoma" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 861, "total_pages": 87, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Colorectal+Adenocarcinoma&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-06-07T10:29:12.205Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT07130903", "title": "Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Metastatic Colorectal Adenocarcinoma" ], "interventions": [ { "name": "Fruquintinib", "type": "DRUG" }, { "name": "TheraBionic P1", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": null, "sex": "ALL", "summary": "22 Years and older" }, "enrollment_count": 102, "start_date": "2025-09-10", "completion_date": "2030-04-17", "has_results": false, "last_update_posted_date": "2025-11-10", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 9, "location_summary": "Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 6 more", "locations": [ { "city": "Bay City", "state": "Michigan" }, { "city": "Clarkston", "state": "Michigan" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Flint", "state": "Michigan" }, { "city": "Lansing", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT07130903" }, { "nct_id": "NCT04474470", "title": "A Study to Evaluate NT219 Alone and in Combination with ERBITUX® (Cetuximab) in Adults with Advanced Solid Tumors and Head and Neck Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Squamous Cell Carcinoma of Head and Neck", "Colorectal Adenocarcinoma", "Metastatic Solid Tumor", "Recurrent Solid Tumor", "Head and Neck Cancer" ], "interventions": [ { "name": "NT219", "type": "DRUG" }, { "name": "NT219 and ERBITUX® - Dose Escalation", "type": "DRUG" }, { "name": "NT219 and ERBITUX® - Expansion", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "TyrNovo Ltd.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 52, "start_date": "2020-09-03", "completion_date": "2024-05-08", "has_results": false, "last_update_posted_date": "2024-09-19", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 7, "location_summary": "Encinitas, California • Los Angeles, California • San Diego, California + 4 more", "locations": [ { "city": "Encinitas", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT04474470" }, { "nct_id": "NCT03539822", "title": "Cabozantinib Plus Durvalumab With or Without Tremelimumab in Patients With Gastroesophageal Cancer and Other Gastrointestinal Malignancies", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastric Cancer", "Esophageal Adenocarcinoma", "Hepatocellular Carcinoma", "Colorectal Cancer" ], "interventions": [ { "name": "Cabozantinib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Anwaar Saeed", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 117, "start_date": "2018-10-22", "completion_date": "2029-06-30", "has_results": false, "last_update_posted_date": "2026-01-21", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 2, "location_summary": "Westwood, Kansas • Pittsburgh, Pennsylvania", "locations": [ { "city": "Westwood", "state": "Kansas" }, { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT03539822" }, { "nct_id": "NCT00942383", "title": "Freehand Ultrasound Elasticity Imaging in Liver Surgery", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Liver Tumors" ], "interventions": [], "intervention_types": [], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "100 Years", "sex": "ALL", "summary": "18 Years to 100 Years" }, "enrollment_count": 15, "start_date": "2007-09", "completion_date": "2012-06-13", "has_results": false, "last_update_posted_date": "2019-03-28", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00942383" }, { "nct_id": "NCT02978625", "title": "Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Anaplastic Large Cell Lymphoma, ALK-Negative", "Anaplastic Large Cell Lymphoma, ALK-Positive", "Apocrine Carcinoma", "Carcinoma Arising From Cylindroma", "Carcinoma Arising From Spiradenoma", "Digital Papillary Adenocarcinoma", "Endocrine Mucin-Producing Sweat Gland Carcinoma", "Extramammary Paget Disease", "Extraocular Sebaceous Carcinoma", "Hidradenocarcinoma", "Malignant Sweat Gland Neoplasm", "Merkel Cell Carcinoma", "Microcystic Adnexal Carcinoma", "NK-Cell Lymphoma, Unclassifiable", "Papillary Adenocarcinoma", "Porocarcinoma", "Primary Cutaneous Mucinous Carcinoma", "Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Recurrent T-Cell Non-Hodgkin Lymphoma", "Refractory Anaplastic Large Cell Lymphoma", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Merkel Cell Carcinoma", "Refractory Mycosis Fungoides", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Refractory Skin Squamous Cell Carcinoma", "Refractory T-Cell Non-Hodgkin Lymphoma", "Sezary Syndrome", "Signet Ring Cell Adenocarcinoma", "Skin Adenoid Cystic Carcinoma", "Skin Adnexal Carcinoma", "Skin Basal Cell Carcinoma", "Skin Basosquamous Cell Carcinoma", "Skin Keratoacanthoma", "Skin Squamous Cell Carcinoma", "Squamoid Eccrine Ductal Carcinoma", "Squamous Cell Carcinoma of Unknown Primary", "Sweat Gland Carcinoma", "Trichilemmal Carcinoma", "Vulvar Squamous Cell Carcinoma" ], "interventions": [ { "name": "Biopsy Procedure", "type": "PROCEDURE" }, { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Positron Emission Mammography", "type": "PROCEDURE" }, { "name": "Talimogene Laherparepvec", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "OTHER", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 68, "start_date": "2017-09-27", "completion_date": "2027-09-01", "has_results": false, "last_update_posted_date": "2026-05-13", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 36, "location_summary": "Los Angeles, California • Orange, California • Pasadena, California + 28 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Pasadena", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02978625" }, { "nct_id": "NCT07318805", "title": "A Study to Learn About the Study Medicine Called PF-08032562 in People With Advanced or Metastatic Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Breast Cancer", "Metastatic Breast Cancer (HR+/ HER2-)", "Colorectal Cancer", "Metastatic Colorectal Adenocarcinoma", "Triple Negative Breast Cancer" ], "interventions": [ { "name": "PF-08032562", "type": "DRUG" }, { "name": "Fulvestrant", "type": "DRUG" }, { "name": "Cetuximab", "type": "DRUG" }, { "name": "Fluorouracil", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 260, "start_date": "2025-12-23", "completion_date": "2030-04-14", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 9, "location_summary": "Duarte, California • Grand Rapids, Michigan • Conroe, Texas + 5 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Grand Rapids", "state": "Michigan" }, { "city": "Conroe", "state": "Texas" }, { "city": "Houston", "state": "Texas" }, { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT07318805" }, { "nct_id": "NCT07023731", "title": "A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "KRAS G12D Mutation", "Advanced Solid Cancer" ], "interventions": [ { "name": "ARV-806", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Arvinas Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 159, "start_date": "2025-05-29", "completion_date": "2029-04-02", "has_results": false, "last_update_posted_date": "2026-02-19", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 14, "location_summary": "Phoenix, Arizona • New Haven, Connecticut • Tampa, Florida + 9 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT07023731" }, { "nct_id": "NCT01638533", "title": "Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Glioma", "Hematopoietic and Lymphoid Cell Neoplasm", "Lymphoma", "Metastatic Malignant Solid Neoplasm", "Neuroendocrine Neoplasm", "Recurrent Adult Soft Tissue Sarcoma", "Recurrent Bladder Carcinoma", "Recurrent Breast Carcinoma", "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Colorectal Carcinoma", "Recurrent Head and Neck Carcinoma", "Recurrent Lung Carcinoma", "Recurrent Malignant Solid Neoplasm", "Recurrent Melanoma", "Recurrent Pancreatic Carcinoma", "Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Recurrent Prostate Carcinoma", "Recurrent Renal Cell Carcinoma", "Recurrent Thyroid Gland Carcinoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma", "Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma", "Stage III Breast Cancer AJCC v7", "Stage III Colorectal Cancer AJCC v7", "Stage III Cutaneous Melanoma AJCC v7", "Stage III Lung Cancer AJCC v7", "Stage III Pancreatic Cancer AJCC v6 and v7", "Stage III Prostate Cancer AJCC v7", "Stage III Renal Cell Cancer AJCC v7", "Stage III Soft Tissue Sarcoma AJCC v7", "Stage IIIA Breast Cancer AJCC v7", "Stage IIIA Colorectal Cancer AJCC v7", "Stage IIIA Cutaneous Melanoma AJCC v7", "Stage IIIB Breast Cancer AJCC v7", "Stage IIIB Colorectal Cancer AJCC v7", "Stage IIIB Cutaneous Melanoma AJCC v7", "Stage IIIC Breast Cancer AJCC v7", "Stage IIIC Colorectal Cancer AJCC v7", "Stage IIIC Cutaneous Melanoma AJCC v7", "Stage IV Breast Cancer AJCC v6 and v7", "Stage IV Colorectal Cancer AJCC v7", "Stage IV Cutaneous Melanoma AJCC v6 and v7", "Stage IV Lung Cancer AJCC v7", "Stage IV Pancreatic Cancer AJCC v6 and v7", "Stage IV Prostate Cancer AJCC v7", "Stage IV Renal Cell Cancer AJCC v7", "Stage IV Soft Tissue Sarcoma AJCC v7", "Stage IVA Colorectal Cancer AJCC v7", "Stage IVB Colorectal Cancer AJCC v7", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Pharmacological Study", "type": "OTHER" }, { "name": "Romidepsin", "type": "DRUG" } ], "intervention_types": [ "OTHER", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2012-08-03", "completion_date": "2020-09-01", "has_results": false, "last_update_posted_date": "2025-02-07", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 11, "location_summary": "Duarte, California • Sacramento, California • Atlanta, Georgia + 8 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT01638533" }, { "nct_id": "NCT06682793", "title": "A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor, Adult", "Colorectal Cancer", "Non-Small Cell Lung", "NSCLC (Non-small Cell Lung Cancer)", "Cancer", "Colon Cancer", "Rectal Cancer", "Lung Cancer", "CRC", "Head and Neck Squamous Cell Cancer", "HNSCC", "Renal Cell Carcinoma", "RCC", "Kidney Cancer", "Triple Negative Breast Cancer", "TNBC", "Colorectal Adenocarcinoma" ], "interventions": [ { "name": "A2B395", "type": "BIOLOGICAL" }, { "name": "xT CDx with HLA-LOH assay", "type": "DIAGNOSTIC_TEST" } ], "intervention_types": [ "BIOLOGICAL", "DIAGNOSTIC_TEST" ], "sponsor": "A2 Biotherapeutics Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2025-05-22", "completion_date": "2030-03-31", "has_results": false, "last_update_posted_date": "2025-09-09", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 10, "location_summary": "Gilbert, Arizona • La Jolla, California • Los Angeles, California + 7 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06682793" }, { "nct_id": "NCT05185791", "title": "ERAS® Guidelines Validation of CRS With or Without HIPEC", "overall_status": "UNKNOWN", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Peritoneal Diseases" ], "interventions": [ { "name": "Pre-ERAS® phase (current clinical practice)", "type": "OTHER" }, { "name": "Post-ERAS® implementation phase", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Hospices Civils de Lyon", "sponsor_class": "OTHER", "healthy_volunteers": null, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 288, "start_date": "2021-10-01", "completion_date": "2022-08-31", "has_results": false, "last_update_posted_date": "2022-01-11", "last_synced_at": "2026-06-07T10:29:12.205Z", "location_count": 1, "location_summary": "Dallas, Texas", "locations": [ { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT05185791" } ] }